Evidence map›Paper›PMID 39995490›Full record

ArticleThe Lancet regional health. Europe2025

Combined use of respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in sickle-cell adult patients with acute chest syndrome (The ANTIBIO-STA study): a randomised, controlled, open-label trial.

Alexandre Sabaté-Elabbadi, Armand Mekontso-Dessap, François Lionnet, Aline Santin, Charlotte Verdet, Paul-Louis Woerther, Julien Lopinto, Matthieu Turpin, Alexandra Rousseau, Romane Lacoste-Badie and 3 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet regional health. Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03919266 (Combined Use of a Respiratory Broad Panel Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Adult Patients With Sickle-cell Disease Hospitalized for Acute Chest Syndrome. A Bi-centric, Open, Parallel-group, Randomized Controlled Study), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03919266 nacompletednot on this map

Combined Use of a Respiratory Broad Panel Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Adult Patients With Sickle-cell Disease Hospitalized for Acute Chest Syndrome. A Bi-centric, Open, Parallel-group, Randomized Controlled Study

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2020 to 2022Enrolled72ConditionsAcute Chest Syndrome, Sickle Cell DiseaseArmsIntervention: Combined use of a respiratory broad panel multiplex PCR and procalcitonin, Control: usual antibiotic treatment
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alexandre Sabaté-ElabbadiSorbonne Université, Assistance Publique - Hôpitaux de Paris, Service de Médecine Intensive Réanimation, Hôpital Tenon, Paris, France.
Armand Mekontso-DessapHôpitaux universitaires Henri Mondor, Assistance Publique - Hôpitaux de Paris, DMU Médecine, Service de Médecine Intensive Réanimation, Hôpital Henri Mondor, Créteil, France.
François LionnetSorbonne Université, Assistance Publique - Hôpitaux de Paris, Service de Médecine Interne, Hôpital Tenon, Paris, France.
Aline SantinSorbonne Université, Assistance Publique - Hôpitaux de Paris, Service de Médecine Interne, Hôpital Tenon, Paris, France.
Charlotte VerdetSorbonne Université, Assistance Publique - Hôpitaux de Paris, Service de Bactériologie, Hôpital Saint-Antoine.
Paul-Louis WoertherHôpitaux universitaires Henri Mondor, Assistance Publique - Hôpitaux de Paris, Service de Microbiologie, Hôpital Henri Mondor, Créteil, France.
Julien LopintoSorbonne Université, Assistance Publique - Hôpitaux de Paris, Service de Médecine Intensive Réanimation, Hôpital Tenon, Paris, France.
Matthieu TurpinSorbonne Université, Assistance Publique - Hôpitaux de Paris, Service de Médecine Intensive Réanimation, Hôpital Tenon, Paris, France.
Alexandra RousseauAssistance Publique - Hôpitaux de Paris, Unité de Recherche Clinique de l'Est Parisien (URC-EST), Hôpital Saint-Antoine, Paris, France.
Romane Lacoste-BadieAssistance Publique - Hôpitaux de Paris, Unité de Recherche Clinique de l'Est Parisien (URC-EST), Hôpital Saint-Antoine, Paris, France.
Keyvan RazaziHôpitaux universitaires Henri Mondor, Assistance Publique - Hôpitaux de Paris, DMU Médecine, Service de Médecine Intensive Réanimation, Hôpital Henri Mondor, Créteil, France.
Guillaume VoiriotSorbonne Université, Assistance Publique - Hôpitaux de Paris, Service de Médecine Intensive Réanimation, Hôpital Tenon, Paris, France.
Muriel FartoukhSorbonne Université, Assistance Publique - Hôpitaux de Paris, Service de Médecine Intensive Réanimation, Hôpital Tenon, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Respiratory infection may account for 30% of acute chest syndrome (ACS) aetiologies. However, antimicrobials are routinely prescribed, and de-escalation and/or discontinuation are challenging. Multiplex Polymerase Chain Reaction (mPCR) with an enlarged respiratory panel might support antimicrobial stewardship, and procalcitonin (PCT) measurements help reduce duration of antibiotic therapy. We hypothesized that a strategy combining the use of mPCR with repeated PCT measurements would reduce antibiotic exposure during ACS. Methods: We conducted a randomised, controlled, parallel group, open-label study in two French hospitals. Consecutive adult patients with ACS were randomly assigned to the conventional or interventional strategy, where antibiotic therapy was targeted on the results of mPCR performed on lower respiratory tract secretions (LRTS) samples, and antibiotic discontinuation based on PCT values and kinetics at Day 1 (D1), D3 and D7. The primary outcome was the number of days of antibiotic exposure at D28 after randomisation. This trial was registered on ClinicalTrial.gov (NCT03919266) and is closed to recruitment. Findings: From June 2020 to September 2022, 72 patients were assigned to the interventional (n = 37) or conventional strategy (n = 35). Despite a higher rate of microbiological documentation with the intervention (n = 25; 67.6% versus n = 13; 37.1%; difference, 30.4%; 95% CI 6.7%-51.5%), antibiotic exposure at D28 was similar between the two strategies (6 days [4.0-8.0] versus 6 days [5.0-9.0], respectively; difference, 0.0 day; 95% CI, -2.1 to 2.1). The time to clinical stability, and ICU and hospital lengths of stay did not differ. Interpretation: As compared with conventional tests, an enlarged respiratory panel mPCR combined with a PCT-guided algorithm did not reduce antibiotic exposure at D28 in adults with ACS. Funding: Assistance Publique-Hôpitaux de Paris, AP-HP (CRC180159). A financial support for the multiplex PCR kits used in this study was partially provided by bioMérieux.

Indexed as

Acute chest syndromeAnti-bacterial agentsMultiplex polymerase chain reactionProcalcitoninSickle cell anemia

Identifiers

PMID39995490
PMCPMC11849121

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.